什么时候应该停止使用心血管药物
Konstantin A Krychtiuk1,2, Bernard J Gersh3, Jeffrey B Washam4
1Duke Clinical Research Institute, 300 W Morgan Street, Durham, NC 27701, USA.
European heart journal
|June 5, 2024
概括
降低心血管药物的处方至关重要,因为指南缺乏长期使用的证据. 停止不必要的药物可以防止伤害,多药,并降低医疗保健成本.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 老年病的医生 老年病的医生
背景情况:
- 在临床实践中,药物开始优先于停止治疗.
- 长期使用药物,特别是老年患者的病情不断变化,缺乏足够的证据和停止药物使用的指导.
- 目前的临床实践指南提供了关于减缓心血管药物的最低建议.
研究的目的:
- 强调需要基于证据的策略来停止心血管药物治疗.
- 为了识别可能需要减缓处方的心血管药物.
- 为了解决与持续,未经证实的药物使用相关的潜在危害.
主要方法:
- 审查现有的临床实践指南和与心血管药物相关的试验证据.
- 关于特定的心血管药物或潜在停药类别的讨论和专家意见.
- 分析与长期药物使用相关的风险,包括不良反应,药物相互作用和多药.
主要成果:
- 有关心血管药物的减缓处方的数据和指导方针存在重大差距.
- 持续服用药物而没有被证明的益处的潜在危害,包括药物相互作用和多药.
- 确定应考虑停止使用的特定心血管药物.
结论:
- 停止处方心血管药物对于患者安全和医疗保健效率至关重要.
- 临床医生和患者应考虑降低处方,以避免潜在的伤害和减少多药性.
- 需要进一步的研究,以制定明确的心血管药物停用指南.
相关概念视频
Cardiovascular Drugs: Classification based on Therapeutic Indications
2.4K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.4K
Assessment of the Cardiovascular System I: Subjective Data
316
A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
316
Imaging Studies for Cardiovascular System I:Echocardiography
314
Cardiac imaging studies encompass a wide range of noninvasive and minimally invasive techniques designed to visualize the heart's structure and function in detail. One such technique is echocardiography, which uses high-frequency ultrasound waves to produce detailed images of the heart, known as echocardiograms.
Indications: Echocardiography is utilized to diagnose heart failure, valve disorders, and myocardial infarction. It also assesses cardiac structures' size, shape, and motion,...
Indications: Echocardiography is utilized to diagnose heart failure, valve disorders, and myocardial infarction. It also assesses cardiac structures' size, shape, and motion,...
314
Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
736
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
736
Drug Elimination: The Concept of Clearance
2.6K
Drug elimination refers to removing drugs from the body, either through urine by the kidneys or through bile by the liver. Drug clearance is a pharmacokinetic parameter that measures the efficiency of drug removal from the bloodstream within a specific time frame. It is calculated as the rate at which a drug is eliminated from plasma divided by the plasma concentration of the drug.
Drug clearance is not limited to renal excretion but encompasses all organs involved in drug elimination,...
Drug clearance is not limited to renal excretion but encompasses all organs involved in drug elimination,...
2.6K


